Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Classifica tra le azioni #4533
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Prezzo delle azioni
$27.18
Ultima sincronizzazione: 2026-07-31
Capitalizzazione di mercato
$3.38B
Variazione (1 giorno)
-1.41%
Variazione (1 anno)
197.05%
Paese
US
Scambia Tango Therapeutics, Inc. (TNGX)

Categoria

Healthcare
Storico del rendimento da dividendi per Tango Therapeutics, Inc. (TNGX)
Il rendimento da dividendi (TTM) di Tango Therapeutics, Inc. (simbolo azionario: TNGX) al 2023-12-31 è: 0.00%
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Tango Therapeutics, Inc. (TNGX) da 2019 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL